

OFFICIAL

JUL 27 2004

Patent
Our Docket: 5019US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Charles A. NICOLETTE


Serial No.: 09/812,238

Filed: March 20, 2001

For: THERAPEUTIC ANTI-MELANOMA
COMPOUNDS

Art Unit: 1654

Examiner: Andrew D. Kosar

Commissioner for Patents
P.O. Box 1450
Alexandria, VA22313-1450I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FACSIMILE TRANSMITTED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE RIGHT FAX NUMBER (703) 872-9306 ON JULY 27, 2004.07/27/04
Date
Deborah A. Dugan

Response to Restriction Requirement

This Communication is being filed in response to a Restriction Requirement mailed May 27, 2004 in connection with the above-identified application. A response to this Restriction Requirement was originally due on June 27, 2004. As part of this communication, Applicant is filing a Petition for a One Month Extension of Time, thereby extending the deadline to file a response to the May 27, 2004 Restriction Requirement to July 27, 2004. Accordingly, this response is timely filed.

In re: Nicolette
USSN: 09/812,238
Filed: March 20, 2001
Page 2

REMARKS

Claims 34-42 are pending in the subject application and are subject to a restriction requirement.

Requirement for Restriction under 35 U.S.C. §121

In the May 27, 2004 Office Action, the Office requires restriction under 35 U.S.C. § 121 to one of the following allegedly independent and distinct inventions:

- | | |
|----------|--|
| Group I | Claims 34-36 and 42, drawn to a composition comprising at least two immunogenic ligands, (e.g., SEQ ID NO:3 and SEQ ID NO:5) and a method of inducing an immune response using said compositions, classified in class 530, subclass 300. |
| Group II | Claims 37-41, drawn to host cell comprising at least two immunogenic ligands (e.g., SEQ ID NO:3 and SEQ ID NO:5) and compositions comprising said host cell, classified in class 435, subclass 325. |

Provisional election under 37 C.F.R. §1.143

Pursuant to 37 C.F.R. §1.143, Applicant's undersigned attorney hereby elects with traverse to prosecute the invention of Group I, claims 34-36 and 42.


CONCLUSION

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

07/27/04

Date


Deborah A. Dugan
Attorney for Applicants
Registration No. 37,315
Telephone: (508) 270-2598
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322